CinCor Pharma, Inc. - Common Stock (NQ:CINC)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 23, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CinCor Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

February 21, 2023

From CinCor Pharma Inc

Via GlobeNewswire

There's a Lot to Love About Mineralys' Valentine's Day IPO

February 13, 2023

MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million

Via MarketBeat

Topics Initial Public Offering

These 2 Healthcare Stocks Have Doubled in 2023

February 01, 2023

Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.

Via MarketBeat

CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

January 24, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Where CinCor Pharma Stands With Analysts ↗

January 12, 2023

Via Benzinga

Where CinCor Pharma Stands With Analysts ↗

December 07, 2022

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)

January 20, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why These Two Biotech Stocks Blasted Higher This Week ↗

January 13, 2023

There's nothing like a big-premium buyout to send a company's share price to the moon.

Via The Motley Fool

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review ↗

January 13, 2023

Sharp Tesla price cuts and some notable earnings were in focus.

Via Investor's Business Daily

CINCOR PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

January 10, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout ↗

January 10, 2023

CinCor will bolster AstraZeneca's growing cardio-renal business.

Via Investor's Business Daily

January 10, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher ↗

January 09, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Monday.

Via Benzinga

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 09, 2023

Via Benzinga

Stocks Building Off Of Friday's Rally ↗

January 09, 2023

The Dow Jones Industrial Average is up more than 280 points midday, while the Nasdaq Composite Index is also up triple digits.

Via Talk Markets

Nasdaq Surges Over 200 Points; Crude Oil Rises 2% ↗

January 09, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday.

Via Benzinga

CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion

January 09, 2023

CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments

Via Spotlight Growth

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal ↗

January 09, 2023

AstraZeneca stock wavered as it agreed to buy CinCor Pharma, maker of blood pressure drug baxdrostat for $1.8 billion. CINC stock soared.

Via Investor's Business Daily

Why Is CinCor (CINC) Stock Up 138% Today? ↗

January 09, 2023

CinCor (CINC) stock is rocketing higher on Monday following news that AstraZeneca (AZN) is acquiring the company for up to $1.8 billion.

Via InvestorPlace

Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday ↗

January 09, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Open Higher; Dow Rises 150 Points ↗

January 09, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday.

Via Benzinga

CINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CinCor Pharma, Inc. Is Fair to Shareholders

January 09, 2023

From Halper Sadeh LLC

Via Business Wire

Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories ↗

January 09, 2023

Bloomberg

Via Benzinga

AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline ↗

January 09, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 09, 2023

Via Benzinga

Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 09, 2023

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

Via InvestorPlace

CinCor Pharma to be Acquired by AstraZeneca

January 09, 2023

From CinCor Pharma Inc

Via GlobeNewswire

Analyzing CinCor Pharma's Short Interest ↗

January 03, 2023

CinCor Pharma's (NASDAQ:CINC) short percent of float has risen 4.28% since its last report. The company recently reported that it has 2.25 million shares sold short, which is 8.78% of all regular...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.